Showing 5321-5330 of 8841 results for "".
- News Your Patients Can Use: AAD Offers Sun Protection Counsel in Advance of Independence Day Holiday Weekendhttps://practicaldermatology.com/news/news-your-patients-can-use-aad-offers-sun-protection-counsel-in-advance-of-independence-day-holiday-weekend/2461819/Remind your patients to use sunscreen on the July 4th weekend and on the days, weeks, and months that follow. A recent American Academy of Dermatology (AAD) survey of more than 1,000 U.S. adults revealed that one-third of American parents reported having a child who
- CHMP Recommends Approval of Leo's Adtralza Pre-filled 2 mL Penhttps://practicaldermatology.com/news/chmp-recommends-approval-of-leos-adtralza-pre-filled-2-ml-pen-5/2461812/The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) is recommending the approval of Adtralza (tralokinumab) in a (300 mg) 2 mL pre-filled pen. With the pre-filled syringe, a single 300-mg dose given every other week rathe
- DataDerm in Action: AAD Launches Project to Improve Outcomes for GPP Patientshttps://practicaldermatology.com/news/aad-launches-project-to-improve-outcomes-for-gpp-patients/2461804/The American Academy of Dermatology is launching a new project to develop educational resources to improve the evaluation, diagnosis, and treatment of patients with generalized pustular psoriasis (GPP). The AAD is working with Boehringer Ingelheim and using OM1’s data aggregation
- Paradigm Shift: Can Harnessing the Power of Healthy Cells Prevent Skin Cancer?https://practicaldermatology.com/news/paradigm-switch-can-harnessing-the-power-of-healthy-cells-prevent-skin-cancer/2461803/Do simple wounds or surgery increase skin cancer risks by expanding mutated cells? No, according to a new study by researchers at Yale and the Karolinska Institute in Sweden. Rather than promoting mutant cell growth, injury promotes healthy-cell expansion which keeps mutated cell growth
- Osteopontin Potently Stimulates Hair Follicle Stem Cells for Robust Hair Growthhttps://practicaldermatology.com/news/osteopontin-potently-stimulates-hair-follicle-stem-cells-for-robust-hair-growth/2461802/Do hairy moles hold the secret to understanding hair growth? Maybe, according to research published in the June 21, 2023 issue of Nature. Using a mouse model, researchers tracked the activity of ha
- Dr. Neil Shah Named New KOL for LASEROPTEK Co. Ltd.https://practicaldermatology.com/news/dr-neil-shah-named-new-kol-for-laseroptek-co-ltd/2461797/Neil Shah, MD, is now a national key opinion leader (KOL) for LASEROPTEK's PALLAS UVB laser system for inflammatory skin conditions. LASEROPTEK's PALLAS laser system is a UVB laser that is US Food and Drug Administration (FDA) -cleared to treat inflammatory skin condit
- Breaking Business News: Lilly to Acquire DICE Therapeuticshttps://practicaldermatology.com/news/breaking-business-news-lilly-to-acquire-dice-therapeutics/2461796/Eli Lilly and Company will acquire DICE Therapeutics, Inc. for a cool $2.4 billion to expand its immunology pipeline. DICE Therapeutics, Inc. is a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic c
- Deloitte Launches 'Illustrate Change' Medical Illustration Libraryhttps://practicaldermatology.com/news/deloitte-launches-illustrate-change-medical-illustration-library/2461794/Deloitte is launching "Illustrate Change," a project that seeks to increase representation in medical i
- Health Canada Greenlights Sun Pharma’s Winlevi for Acnehttps://practicaldermatology.com/news/health-canada-greenlights-sun-pharmas-winlevi-for-acne/2461792/Health Canada has given its nod to Sun Pharma’s Winlevi (clascoterone cream 1%). Winlevi an androgen receptor inhibitor indicated for the topical treatment of acne vulgaris in patients 12 years of age and older. It will be available in Canada this Fall. "
- Sirnaomics Gets FDA Go Ahead to Move STP705 Into Late-Stage Clinical Development for isSCChttps://practicaldermatology.com/news/sirnaomics-gets-fda-go-ahead-to-move-stp705-into-late-stage-clinical-development-for-isscc/2461788/Sirnaomics Ltd.’s STP705 for the treatment of Squamous Cell Carcinoma in situ (isSCC) is moving into late-stage clinical development after encouraging Phase IIa and Phase IIb clinical results. These results were shared with the U.S. Food and Drug Administration (FDA) in an En